# Management of Newborns of Mothers with TB Disease

Nicole Salazar-Austin, MD ScM Assistant Professor of Pediatrics Johns Hopkins School of Medicine 27 September 2024



## Outline

- 1) Burden of TB disease in pregnancy
- 2) Consequences to infant
- 3) Perinatal vs Congenital TB
- 4) Management of infants born to mothers with TB
  - Evaluation
  - Treatment
  - Isolation & breastfeeding

## TB Burden in Pregnancy is Likely High but Unknown



Global TB Report 2023

## TB Burden in Pregnancy is Likely High but Unknown



Data on TB & pregnancy is not commonly collected by TB programmes

#### TB Burden in Pregnancy is Likely High but Unknown

#### 10.6 Million People with TB in 2022





Number of TB cases

#### **TB Risk in Peripartum Women and Children**





TB incidence is **2x higher** postpartum than non-pregnant/non-postpartum

Other children in the household are

also at high risk of disease

## Four-symptom WHO TB Screen has Poor Sensitivity in Pregnancy



Additional screening methods may be needed to identify pregnant women with TB/HIV

## Increased Identification of TB in PWLHIV through Universal Screening

#### Methods

- Cluster-randomized trial of universal vs symptom-based testing in pregnant PLHIV
- Testing: Xpert only  $\rightarrow$  Xpert + MGIT culture

#### Conclusions

- 10-fold increased detection of TB in universal vs symptom based scrn
- Xpert detects one third the rate of TB compared to MGIT ?low bacillary load
- Halved infant and maternal deaths (not statistically significant)

Xpert	MTB/RIF	v MGIT	Culture:	Universal
Aport			Outture.	Universa



Yield of TB by Arm, by Visit and by Site					
Study Arn	n n/N	MTb Yield (95%CI)	Baseline	Matlosana (high burden)	Vhembe (medium burden)
Universal	34/941	3.6% (1.2-6.0)	26/34	4.5%	2.2%
Symptom	4/1100	0.36% (0.0-1.1)	4/4	0%	1.1%

#### **Increased Adverse Maternal and Pregnancy Outcomes**

- 4-fold increased maternal mortality
- 3-fold increase morbidity
- > 10-fold increased hospitalization
- 4-fold increase anemia
- 2-fold increase cesarean
- 9-fold increase miscarriage



Sobhy BJOG 2017

## Increased Adverse Infant Outcomes

Study		*
ID		OR (95% 0) weight TB affected TB total Control affected Control
Perinatal death Ricardo Figueroa- Damian- 2001	_ =	9.75 (0.98, 97.01) 12.07 3 35 1 105
N. Jana, 1999		4.23 (0.57, 31.18) 14.11 2 33 2 133
N, Jana, <u>1</u> 994		7.01 (2.23, 22.06) 21.78 8 79 5 318
Ricardo Figueroa- Damian- 1998		23.49 (1.17, 471.95),51 3 25 0 75
P.A. Kavganko, 2003 -		2.31 (0.12, 45.00) 8.63 3 371 0 121
I.Bjerkedal, 1975		1.00 (0.50, 2.02) 26.16 8 546 1657 113 511
Adolfas Pranevieius,2003		- 8.88 (0.47, 167, 88) 8.76 4 77 0 72
Subtotal (I <sup>2</sup> = 57.2%, P = 0.029)		4.20 (1.49, 11.83) 100.00
Low birth weight		
Lin, 2009		1.36 (1.02, 1.91) 25.82 85 761 244 3905
Inpathy, 2003		1.13 (0.54, 2.37) 13.22 33 110 14 51
A.All, 2011		2.40 (0.80, 7.16) 7.84 12 42 6 42
N. Jana, 1999		2.70 (1.02, 7.11) 9.32 8 33 14 132
N. Jana, 1994 B.A. Kayapaka, 2002		2.64 (1.62, 4.66) 17.69 27 78 62 316 5.66 (1.40, 65.66) 5.65 34 370 0 101
T Riorkodol 1075		1 07 0 00 1 00 01 00 01 072 2 121
	~	1.71 (1.00 (1.00) 21.00 21 0.01 4144 112.000
Subtotal ( $I^2 = 53.7\%$ , $P = 0.044$ )	$\sim$	1.71 (1.20, 2.4a) 100.00
Pre-term birth		3.44 (0 TD 9 ED) 5 60 5 04 7 73
Asuguo- 2012		2,44 (0,70,8,56) 0,50 5 24 7 72 1,01,01,76 1,945 11 761 975 955
Ricardo Figueroa, Damian, 2001		9.99.00.00.12.00.5.40.5. 95.5. 105
	-	170 0 81 4 721 7 88 12 42 8 42
N Jana 1999		1.22 (0.32 4.71) 5.22 3 33 10 132
N Jana 1994		2.37 (1.26, 4.46) 12.42 18 78 35 315
A Marvnowski 1971		2.32 (1.75, 5.08) 17.99 118 1188 91 2007
PA Kavganko 2004		1.27 (0.48, 3.53) 7.67 8 96 8 120
T Bierkedal 1975		1.05 (0.71, 1.55) 16.37 27 516 5431 108 622
Bicardo Figueroa- Damian- 1998	T	8.86 (1.17, 40.06) 3.42 4 25 2 74
Subtotal ( $I^2 = 66.5\%$ , $P = 0.001$ )	$\diamond$	1.68 (1.18, 2.41) 100.00
Acute fetal distress		
N, Jana, 1994		2.85 (1.24, 5.69) 72.14 12 79 20 S18
N. Jana, 1999		1.68 (0.49, 5.75) 27.85 4 33 10 132
Subtotal (l <sup>2</sup> = 0.0%, P = 0.538)	$\sim$	2.34 (1.22, 4.47) 100.00
Asphyxia	_	
Adolfas Pranevièius,2003		3.24 (1.11, 8.45) 24.00 15 77 5 72
P.A. Kavganko, 2004		3.12 (1.44, 6.79) 35.00 23 96 11 120
P.A. Kavganko, 2003		7.88 (3.98, 14.81) 41.00 142 327 11 121
Subtotal (I <sup>2</sup> = 46.3%, P = 0.155)	$\sim$	4.55 (2.40, 8.65) 100.00
NOTE: waights are from random attacks analysis		
The rest weights and includes output the second straights		
0.00212		472
0.00212	1	7/6

- 4-fold increased perinatal death 2-fold increase LBW
  - 2-fold increased preterm birth
  - 2-fold increase acute fetal distress
  - 5-fold increase birth asphyxia

Active TB better outcomes Active TB poorer outcomes

#### Poor Infant Outcomes Associated with Subclinical TB

Obstetric outcomes	TB-negative controls (n = 151) n (%)	Unsuspected prevalent TB (n = 7) n (%)	P value (prevalent vs. controls)	TB-positive cases (n = 70) n (%)
Outcome of pregnancy Live birth Spontaneous abortion Stillbirth Composite maternal complications outcome <sup>†</sup>	149* (99) 0 2 (1) 53 (35)	7 (100) 0 0 3 (43)	1.0	67 (96) 1 (1) 2 (3) 31 (44)
Infant outcomes HIV transmission Infant TB	(n = 150)* 2 (1) 0	(n = 7) 0 1 (14)	1.0 0.045	(n = 67) 3 (4) 8 (12)
Neonatal sepsis Infant hospitalization Infant death Composite infant complications outcome <sup>‡</sup>	6 (4) 16 (11) 1 (1) 17 (11)	1 (14) 3 (43) 0 3 (43)	0.3 0.039 1.0 0.045	3 (4) 11 (16) 5 (7) 16 (24)

**Table 2**Obstetric and infant outcomes by TB status

## Infants of mothers with HIV & subclinical TB had higher risk of adverse infant outcomes (TB & hospitalization) than mothers with HIV alone

## Maternal TB integrated into the Child TB Roadmap



#### Key actions needed for maternal TB:

- Better understanding of the burden of TB disease in pregnant women
- 2) Pregnant and post-partum women and their infants should be protected through and not from research; urgent need to include pregnant women and their infants in TB drug & vaccine trials
- 3) Rigorous operational research and surveillance will enable rapid detection of uncommon adverse maternal, pregnancy and birth outcomes

## **Perinatal Tuberculosis**

#### **Congenital TB**

In utero infection of fetus with M.tb (rare)

Maternal TB bacillemia (primary or disseminated) Results in dissemination of infection to placenta, endometrium or genital tract

#### **Postnatal TB**

Post natal infection of infant (common)

Maternal infectious pulmonary disease (untreated cavitary disease, etc.)

#### **Transplacental transmission**

- Maternal hematogenous spread
- Primary focus in infant liver (fetal circulation)

#### **Aspiration/Ingestion fluid**

- Maternal endometritis or placental infection
- Primary focus in lung or GI tract





#### **Airborne transmission**

- Maternal infectious pulmonary TB
- Primary focus in lung

## Congenital Tuberculosis: Diagnostic Criteria

#### **Cantwell Criteria**

Presence of proven tuberculosis disease in the infant with at least one of the following:

- Lesions in the newborn during the first week of life
- Primary hepatic complex or caseating hepatic granuloma
- TB infection of the placenta or maternal genital tract
- Exclusion of possibility of postnatal transmission by investigation of contacts, including hospital staff

Criteria are rather strict, difficult to prove even in resource-rich settings

## Congenital TB: Signs & Symptoms

#### Non-specific signs and symptoms

- Ill neonate with fever, tachypnea, lethargy, organomegaly, pulmonary infiltrates
- Median time to presentation: 2-3 weeks (range 1-112 days)
- Combined data from 75 cases in 38 case reports/series:

Common (>40%)	Frequent (25-40%)	Infrequent (10-25%)	Rare (< 10%)
<ul> <li>Respiratory Distress (incl tachypnea)</li> <li>Hepatosplenomegaly</li> <li>Fever (often low-grade)</li> <li>Prematurity/LBW</li> </ul>	<ul> <li>Cough – acute or chronic</li> <li>Poor feeding</li> <li>Failure to thrive</li> <li>Abdominal distension (incl ascites)</li> </ul>	<ul> <li>Irritability</li> <li>Peripheral LAD</li> <li>Sepsis syndrome</li> </ul>	<ul> <li>Skin lesions</li> <li>TB meningitis</li> <li>Jaundice (obstructive)</li> <li>Otorrhea/mastoiditis</li> <li>Wheeze/stridor</li> <li>Apnea/cyanosis (BRUE)</li> </ul>

- Facial nerve palsy
- Shock

## Management of the infant born to a mother with tuberculosis: a systematic review and consensus practice guideline

Nadia Hasan, Clare Nourse, H Simon Schaaf, Adrie Bekker, Marian Loveday, Betina M Alcântara Gabardo, Christopher Coulter, Chishala Chabala, Sushil Kabra, Eilish Moore, Elizabeth Maleche-Obimbo, Nicole Salazar-Austin, Nicole Ritz, Jeffrey R Starke, Andrew P Steenhoff, Rina Triasih, Steven B Welch, Ben J Marais

- 1) Systematic Review
  - MEDLINE, CINAHL & Cochrane Library through December 1, 2022
  - 521 published papers  $\rightarrow$  3 met inclusion criteria  $\rightarrow$  no evidence-based conclusions
  - Narrow scope, variable aims, descriptive nature, inconsistent data collection, high attrition rates
- 2) Consensus Guideline
  - Reviewed 16 international guidelines
  - International panel of experts from high/low burden and high/low resource settings
  - Developed guidance for mothers who were potentially infectious and non infectious at delivery

#### Purpose:

- More consistent clinical management
- Support the collection of better data
- Encourage the development of more studies to improve evidence-based care

## Management of Infant Born to Mother with Potentially Infectious TB at Delivery



#### **Maintain High Suspicion** Maternal TB may not be diagnosed at the time of infant presentation! 2 months is conservative Considers: Maternal resistance Other ill/infectious household members ۰ Culture/smear conversion may not be documented until 2 months Maternal disease with increased risk of congenital TB Disseminated TB (miliary or TBM) Tuberculous pleural effusion (suggestive of recent primary infection) Pelvic, genital or placental TB

Lancet Child Adolesc Health 2024;8:369–78

## **Comprehensive Clinical Assessment**

#### Routine:

- Chest X-ray
- Abdominal US
  - Not always available in all settings
  - Especially important when mom is high risk for transplacental transmission

With any signs or symptoms:

- Abdominal US: if IUGR, hepatomegaly, and/or ascites
- **Respiratory specimens** for culture and/or NAAT
- Lumbar Puncture for cell counts, chemistries, culture, NAAT
- Fundoscopy (maternal)
- **Brain imaging** (if signs/symptoms CNS disease)
  - MRI > CT > Head US

## Management of Infant Born to Mother with Non-infectious TB at Delivery

#### **High burden setting**



Lancet Child Adolesc Health 2024;8:369–78

## Management of Infant Born to Mother with Non-infectious TB at Delivery

#### **High burden setting**

#### Low burden setting



## Maternal TB & Breastfeeding



- Breast is best
- Every effort should be made to facilitate breastfeeding
- Minimize mother-infant isolation: transmission low once mother on treatment and infant on TPT
  - Surgical mask can be used if mom considered infectious
  - Or no mask if mother has good adherence with treatment response
- Minimal data on TB drugs in breastmilk
  - RHZE low levels in breastmilk, no direct measures in infants, no known safety concerns
  - Less experience and fewer data with second line medications
  - Lipophilic drugs like BDQ have high BM concentrations in animals and humans and may have therapeutic exposures in infants
  - WHO-led consensus process to encourage the optimal and early inclusion of pregnant women in TB drug and vaccine research

## Maternal TB & Adolescents

- Adolescents are at high risk of progression from infection to disease
- Pregnant adolescents may be more likely to experience obstetric & neonatal complications
- High risk of poor adherence resulting in treatment failure, relapse, and resistance with resulting transmission to their infants



## Take Home Messages

- Perinatal TB is relatively common; true congenital TB is rare
  - Can be acute and atypical
  - Infants born to mothers with TB can also be exposed by other household members
- High index of suspicion in mothers and infants is required
- Optimal TB screening for mother (particularly if living with HIV) is unknown
- New expert opinion consensus treatment guidelines are available
- Facilitate breastfeeding transmission low once mother is on treatment and infant is on prophylaxis

## Thank you